By Staff
Monday, June 17, 2024 12:21 AM
ALISO VIEJO, Calif.—
Glaukos Corporation, an ophthalmic pharmaceutical and medical tech company, has announced that it entered into separate, privately negotiated exchange agreements with certain holders of its 2.75 percent convertible senior notes due 2027.
By Staff
Friday, May 31, 2024 12:30 AM
CooperCompanies announces Q2 2024 financial results; KeraLink International names a new president and CEO; Merck to acquire EyeBio; CooperCompanies publishes 2023 ESG report; and The Vision Council releases new inSights research all topped this week’s
VMAIL news feed. Click on the headlines below to catch up on anything you might have missed.
By Staff
Friday, May 31, 2024 12:27 AM
SAN RAMON, Calif.—
CooperCompanies (Nasdaq: COO), a global medical device company, has announced financial results for its fiscal second quarter ended April 30, 2024. CooperCompanies reported revenues under two major segments—CooperVision (CVI) and CooperSurgical (CSI). The company reported that overall revenue increased 7 percent year-over-year to $942.6 million. CVI revenue was up 8 percent to $635.9 million and CSI revenue grew 6 percent to $306.7 million, according to the announcement. "I'm pleased to report record quarterly revenues and great operational progress throughout the organization," said Al White, Cooper's president and CEO.
By Staff
Thursday, May 30, 2024 12:21 AM
RAHWAY, N.J. and NEW YORK—
Merck (NYSE: MRK), known as MSD outside of the U.S. and Canada, and
Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, announced that the companies have entered into a definitive agreement under which
Merck, through a subsidiary, will acquire EyeBio. Under the terms of the agreement, Merck will acquire all outstanding shares of EyeBio for up to $3 billion, including an upfront payment of $1.3 billion in cash and a further potential $1.7 billion in developmental, regulatory and commercial milestone payments, the announcement stated. The acquisition has been unanimously approved by the EyeBio board of directors.
By Staff
Thursday, May 30, 2024 12:18 AM
MIAMI—
Innovative Eyewear, Inc., a developer and seller of smart eyewear, has announced that it has entered into a definitive agreement for the issuance and sale of 5,263,161 shares of its common stock at a purchase price per share of $0.475 in a registered direct offering priced at-the-market under Nasdaq rules.
By Staff
Friday, May 24, 2024 12:24 AM
MARLBOROUGH, Mass.—
BJ’s Wholesale Club Holdings, Inc. (NYSE: BJ) has announced its financial results for the thirteen weeks ended May 4, 2024. Total comparable club sales increased by 1.6 percent in the first quarter of fiscal 2024 compared with the first quarter of fiscal 2023.
By Staff
Friday, May 24, 2024 12:21 AM
MUNICH—
Rodenstock Group, a global innovation leader in vision care and manufacturer of biometric lenses, has announced its results for the financial year 2023.
By Staff
Wednesday, May 22, 2024 12:18 AM
Editor's Note: A version of this article that appeared in VMAIL on May 16, 2024, incorrectly reported the monetary units. This version reflects corrected monetary units.
TOKYO—
Hoya Corporation has announced consolidated revenue of 196.8 billion yen for the fourth quarter ending March 31, 2024, up 6 percent from year-ago.
By Staff
Tuesday, May 21, 2024 12:24 AM
LONGARONE, Italy—The
De Rigo Group board of directors has approved the results for the year 2023 with a consolidated turnover of €506.1 million compared with €452.7 million in 2022, representing an increase of 11.8 percent. At constant exchange rates, the increase compared with 2022 was 16 percent, according to the company. Net sales in the Americas for 2023 grew by 5.1 percent to €57.5 million, compared with €54.7 million in 2022. At 2022 exchange rates, the net sales achieved in this region amounted to €58.8 million, the company said.
By Staff
Friday, May 17, 2024 12:24 AM
BENTONVILLE, Ark.—
Walmart Inc. (NYSE: WMT) has announced first quarter financial results for the three months ending on April 30, 2024, showcasing strong growth in revenue and operating income. The results shared by the omnichannel, global retailer are for Q1 of its 2025 fiscal year, which runs for 12 months ending January 31, 2025. Specific highlights for the first quarter include consolidated revenue of $161.5 billion, up 6.0 percent, or 5.8 percent constant currency versus the same period last year; reported operating income up $0.6 billion (9.6 percent) and adjusted operating income up 13.7 percent, attributed to higher gross margins and growth in membership income; and growth in global e-commerce sales by 21 percent, led by store-fulfilled pickup/delivery and marketplace.
By Staff
Friday, May 17, 2024 12:21 AM
OBERKOCHEN, Germany—The
Zeiss Group has reported the results of the first half of fiscal year 2023/24. The group generated revenue totaling €5.304 million for the period ended March 31, 2024.
By Staff
Thursday, May 16, 2024 12:24 AM
Editor's Note: A version of this article that appeared in VMAIL on May 16, 2024, incorrectly reported the monetary units. This version reflects corrected monetary units.
TOKYO—
Hoya Corporation (7741:Tokyo) has announced consolidated revenue of 196.8 billion yen for the fourth quarter ending March 31, 2024, up 6 percent from year-ago, and down 1 percent on a constant currency basis. Pretax profit rose to 72.1 billion yen, a 34 percent increase versus year-ago, up 27 percent with the constant currency effect. Operating profit slipped 1 percent to 53 billion yen compared to the prior-year period, a decrease of 5 percent in constant currency, according to Hoya.
By Staff
Thursday, May 16, 2024 12:21 AM
NEW YORK—
Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, has announced its financial and operating results for the quarter ended March 31, 2024.
By Staff
Wednesday, May 15, 2024 12:24 AM
GENEVA—
Alcon (SIX/NYSE:ALC), a global leader in eyecare, reported its financial results for the three months ended March 31, 2024. Sales were $2.4 billion, for the first quarter of 2024, an increase of 5 percent on a reported basis and 7 percent on a constant currency basis, compared with Q1 of 2023. "Our first-quarter results reflect the outstanding work done by our more than 25,000 associates across both our surgical and vision care franchises," said David J. Endicott, Alcon's chief executive officer.
By Staff
Wednesday, May 15, 2024 12:21 AM
NASHVILLE, Tenn.—
Harrow, a U.S. eyecare pharmaceutical company, (Nasdaq: HROW) has announced its results for the first quarter ended March 31, 2024. In the first quarter of 2024, Harrow recorded revenues of $34.6 million, a 33 percent increase over the $26.1 million realized in the prior-year quarter.